Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients
暂无分享,去创建一个
B. Merriman | Hee-Jin Kim | Sun-Hee Kim | H. Won | Inho Park | Jong-Won Kim | C. Jung | Hongseok Yun | Choong-Hyun Sun | Seungmook Lee | S. Bang | Seung-Tae Lee | H. Chi | Eun-Hyung Yoo | Jong-Ho Park | Eileen Hwee-Hong Tan | R. Luo | Na-Kyung Yoo | June-Hee Park | Keun‐Joon Park | Clarence Lee | Kyung‐Jin Park | J. Kang
[1] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[2] M. Cazzola,et al. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. , 2014, Blood.
[3] T. Golub,et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. , 2014, Blood.
[4] R. Yang,et al. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment , 2014, Leukemia.
[5] Christian Beisel,et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. , 2014, Blood.
[6] M. Cazzola,et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. , 2014, Blood.
[7] P. Guglielmelli,et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. , 2014, Blood.
[8] A. Tefferi,et al. Genetics: CALR mutations and a new diagnostic algorithm for MPN , 2014, Nature Reviews Clinical Oncology.
[9] G. Superti-Furga,et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.
[10] J. D. Fitzpatrick,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.
[11] Y. Hinoda,et al. JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients , 2013, International Journal of Hematology.
[12] M. Guan,et al. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients , 2012, International Journal of Hematology.
[13] O. Abdel-Wahab,et al. The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.
[14] C. von Mering,et al. PaxDb, a Database of Protein Abundance Averages Across All Three Domains of Life , 2012, Molecular & Cellular Proteomics.
[15] Huanming Yang,et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.
[16] Huanming Yang,et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.
[17] L. Scott,et al. The JAK2 exon 12 mutations: A comprehensive review , 2011, American journal of hematology.
[18] L. Bullinger,et al. DNMT3A mutations in myeloproliferative neoplasms , 2011, Leukemia.
[19] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[20] Erin F. Simonds,et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. , 2010, Blood.
[21] H. Drexler,et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.
[22] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[23] P. Campbell,et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. , 2010, Blood.
[24] A. Tefferi,et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms , 2010, Leukemia.
[25] M. Cazzola,et al. The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera , 2009, Leukemia.
[26] R. Levine,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[27] Ashot Harutyunyan,et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms , 2009, Nature Genetics.
[28] Kenneth Offit,et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms , 2009, Nature Genetics.
[29] Andrew Collins,et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms , 2009, Nature Genetics.
[30] B. Fridley,et al. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. , 2008, Blood.
[31] M. Cazzola,et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. , 2008, Blood.
[32] D. Gilliland,et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.
[33] Sandra A. Moore,et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.
[34] M. Wadleigh,et al. The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera , 2006, Cancer.
[35] S. Verstovsek,et al. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? , 2006, Leukemia.
[36] C. Carlson,et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. , 2004, American journal of human genetics.